- Home
- EVC vs GOSS Comparison
EVC vs GOSS Comparison
Compare EVC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVC
- GOSS
- Stock Information
- Founded
- EVC 1996
- GOSS 2015
- Country
- EVC United States
- GOSS United States
- Employees
- EVC N/A
- GOSS N/A
- Industry
- EVC Broadcasting
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- EVC Industrials
- GOSS Health Care
- Exchange
- EVC Nasdaq
- GOSS Nasdaq
- Market Cap
- EVC 185.4M
- GOSS 214.7M
- IPO Year
- EVC 2000
- GOSS 2019
- Fundamental
- Price
- EVC $2.32
- GOSS $0.96
- Analyst Decision
- EVC Hold
- GOSS Strong Buy
- Analyst Count
- EVC 1
- GOSS 5
- Target Price
- EVC $1.75
- GOSS $9.20
- AVG Volume (30 Days)
- EVC 219.2K
- GOSS 910.5K
- Earning Date
- EVC 10-31-2024
- GOSS 11-07-2024
- Dividend Yield
- EVC 8.64%
- GOSS N/A
- EPS Growth
- EVC N/A
- GOSS N/A
- EPS
- EVC N/A
- GOSS N/A
- Revenue
- EVC $1,126,331,000.00
- GOSS $95,842,000.00
- Revenue This Year
- EVC N/A
- GOSS N/A
- Revenue Next Year
- EVC N/A
- GOSS N/A
- P/E Ratio
- EVC N/A
- GOSS N/A
- Revenue Growth
- EVC 65.95
- GOSS N/A
- 52 Week Low
- EVC $1.33
- GOSS $0.45
- 52 Week High
- EVC $4.41
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- EVC 67.75
- GOSS 48.30
- Support Level
- EVC $2.05
- GOSS $0.93
- Resistance Level
- EVC $2.15
- GOSS $1.09
- Average True Range (ATR)
- EVC 0.08
- GOSS 0.05
- MACD
- EVC 0.02
- GOSS -0.01
- Stochastic Oscillator
- EVC 96.73
- GOSS 20.31
About EVC Entravision Communications Corporation
Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.